Related Experiment Video

Updated: Jan 2, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.8K

Filanesib for the treatment of multiple myeloma

Esperanza Macarena Algarín1, Susana Hernández-García1, Mercedes Garayoa1

  • 1Cancer Research Center (IBMCC-CSIC-USAL), University Hospital of Salamanca (IBSAL), Salamanca, Spain.

Expert Opinion on Investigational Drugs
|December 10, 2019
PubMed

Insights

Filanesib, a kinesin spindle protein inhibitor, shows promise for treating multiple myeloma. Its efficacy is enhanced when combined with other therapies, and a biomarker may identify suitable patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Kinesin spindle protein (KSP) is crucial for mitosis and a cancer treatment target.
  • KSP inhibitors show preclinical anticancer effects but limited clinical success.
  • Filanesib, a KSP inhibitor, has demonstrated clinical efficacy in multiple myeloma (MM).

Purpose of the Study:

  • To provide a comprehensive overview of filanesib's preclinical and clinical development for cancer, especially MM.
  • To discuss filanesib's efficacy, combination therapies, and response biomarkers in MM treatment.

Main Methods:

  • Review of preclinical data on filanesib's antitumoral effects.
  • Analysis of clinical trial results for filanesib in various cancer types, focusing on MM.
  • Evaluation of combination therapies involving filanesib with other MM treatments.
  • Discussion of potential response biomarkers for filanesib therapy.

Main Results:

  • Filanesib demonstrated encouraging responses in MM patients, alone and with dexamethasone.
  • Combination therapies with carfilzomib and pomalidomide showed interesting results.
  • The development of newer agents has impacted filanesib's clinical progression.

Conclusions:

  • Filanesib shows potential in MM treatment, particularly in combination regimens.
  • Alpha 1-acid glycoprotein (AAG) may serve as a predictive biomarker for filanesib treatment response.
  • Identifying patient subgroups who benefit most from filanesib combinations is crucial.
Keywords:
ARRY-520Eg5KSPfilanesibmultiple myeloma

More Related Videos

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

6.4K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K